Corneal collagen cross-linking (CXL) is a noninvasive technique developed to treat patients with thinned or weakened corneas, most commonly seen in a disease called keratoconus. In keratoconus, the cornea (the front clear window of the eye) can become weak, thin, and irregularly shaped. Instead of keeping its normal round shape, corneas with keratoconus can bulge forward into the shape of a cone causing poor vision. CXL is now being performed for patients with this condition in approximately 450 centers throughout the world to help stabilize the cornea and prevent the need for corneal transplantation surgery. This technology was only recently approved by the Food and Drug Administration despite being widely used in the rest of the world for several years. Our practice is now able to provide this proven treatment to our patients using advanced technology for cross-linking.